AMPLIA THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 AUD | +1.56% |
|
+6.56% | -18.75% |
| 04-16 | Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing | MT |
| 03-27 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
| Sales 2022 | 1.98M 1.3M 104M | Sales 2023 | 1.19M 777K 62.2M | Capitalization | 16.49M 10.77M 862M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -1.96M -157M | Net income 2023 | -6M -3.92M -314M | EV / Sales 2022 | 7.87 x |
| Net cash position 2022 | 12.51M 8.17M 654M | Net cash position 2023 | 6.98M 4.56M 365M | EV / Sales 2023 | 7.99 x |
| P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-2.64
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.56% | ||
| 1 week | +6.56% | ||
| Current month | -15.58% | ||
| 1 month | -15.58% | ||
| 3 months | -18.75% | ||
| 6 months | -21.69% | ||
| Current year | -18.75% |
1 week
0.06
0.07
1 month
0.060.09
Current year
0.060.09
1 year
0.060.12
3 years
0.060.35
5 years
0.050.37
10 years
0.0518.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 30/05/00 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 24/09/23 |
Rhiannon Jones
COO | Chief Operating Officer | - | 31/01/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 10/10/13 |
Robert Peach
BRD | Director/Board Member | 68 | 01/09/15 |
Warwick Tong
CHM | Chairman | - | 03/05/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.065 | +1.56% | 9,230 |
| 24/04/24 | 0.064 | +6.67% | 342,635 |
| 23/04/24 | 0.06 | -7.69% | 191,395 |
| 22/04/24 | 0.065 | +6.56% | 649 |
Delayed Quote Australian S.E., April 26, 2024 at 01:35 am
More quotes
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Companyâs pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Companyâs second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
Calendar
26/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.75% | 8.22M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ATX Stock
